Lung adenocarcinomas with mucinous histology: clinical, genomic, and immune microenvironment characterization and outcomes to immunotherapy-based treatments and KRAS^G12C inhibitors.

ABSTRACT:

Background

Approximately 10% of lung adenocarcinomas (LUADs) have mucinous histology (LUAD^Muc), which is associated with a light/absent smoking history and a high prevalence of KRAS mutations. We sought to characterize LUAD^Muc by comparing it with LUAD without mucinous histology (LUAD^non-muc) and determine the relative benefit of current treatments.

Patients and methods

Patients with LUAD from five institutions and The Cancer Genome Atlas Pan-Cancer Atlas classified as LUAD^Muc or LUAD^non-muc were included. Clinicopathologic, genomic, immunophenotypic, transcriptional features, and treatment outcomes were compared between LUAD^Muc and LUAD^non-muc.

Results

Of 4082 patients with LUAD, 9.9% had LU

SUBMITTER: Di Federico A 

PROVIDER: S-EPMC11845285 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature